Proteasome inhibitors in cancer therapy

Lisa Crawford, Brian Walker, Alexandra Irvine

Research output: Contribution to journalArticle

193 Citations (Scopus)


The ubiquitin proteasome pathway plays a critical role in regulating many processes in the cell which are important for tumour cell growth and survival. Inhibition of proteasome function has emerged as a powerful strategy for anti-cancer therapy. Clinical validation of the proteasome as a therapeutic target was achieved with bortezomib and has prompted the development of a second generation of proteasome inhibitors with improved pharmacological properties. This review summarises the main mechanisms of action of proteasome inhibitors in cancer, the development of proteasome inhibitors as therapeutic agents and the properties and progress of next generation proteasome inhibitors in the clinic.
Original languageEnglish
Pages (from-to)101-110
Number of pages10
JournalJournal of Cell Communication and Signaling
Issue number2
Publication statusPublished - Jun 2011

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Fingerprint Dive into the research topics of 'Proteasome inhibitors in cancer therapy'. Together they form a unique fingerprint.

  • Cite this